Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Massard

Showing results (21-30 of 364) with videos related to

Pageof 37
Sort By:
Bulletin Du Cancer|March 18, 2015
[Recent evolutions in metastatic melanoma]Christophe Massard, Céleste Lebbé, Stéphane Vignot
Bulletin Du Cancer|December 8, 2011
[Metronomic chemotherapy in 2011: update and perspectives]Zineb Benbrahim, Christophe Massard, Omar El Mesbahi
Clinical Genitourinary Cancer|January 7, 2011
Changing therapeutic paradigms in castrate-resistant prostate cancerAndrea Zivi, Christophe Massard, Johann De-Bono
NDT Plus|May 19, 2015
Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMAHassane Izzedine, Christophe Massard, Jean Charles Soria
Bulletin Du Cancer|January 24, 2013
[Prognostic factors for patients with brain metastases]Romuald Le Scodan, Christophe Massard, Georges Noël
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
From theoretical synergy to clinical supra-additive toxicityJean-Charles Soria, Christophe Massard, Hassane Izzedine
Current Opinion in Oncology|April 9, 2014
Implementing precision medicine initiatives in the clinic: a new paradigm in drug developmentAntoine Hollebecque, Christophe Massard, Jean-Charles Soria
Current Opinion in Oncology|March 14, 2012
Vascular disrupting agents: a delicate balance between efficacy and side effectsAntoine Hollebecque, Christophe Massard, Jean-Charles Soria
Current Urology Reports|December 6, 2011
Targeted therapies in metastatic renal cell carcinoma: overview of the past yearMarine Gross-Goupil, Christophe Massard, Alain Ravaud
European Urology|January 31, 2022
Re: Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau DiseaseKarim Bensalah, Zine-Eddine Khene, Christophe Massard
Pageof 37

Showing results (21-30 of 364) with videos related to

Sort By:
Pageof 37
Bulletin Du Cancer|March 18, 2015
[Recent evolutions in metastatic melanoma]Christophe Massard, Céleste Lebbé, Stéphane Vignot
Bulletin Du Cancer|December 8, 2011
[Metronomic chemotherapy in 2011: update and perspectives]Zineb Benbrahim, Christophe Massard, Omar El Mesbahi
Clinical Genitourinary Cancer|January 7, 2011
Changing therapeutic paradigms in castrate-resistant prostate cancerAndrea Zivi, Christophe Massard, Johann De-Bono
NDT Plus|May 19, 2015
Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMAHassane Izzedine, Christophe Massard, Jean Charles Soria
Bulletin Du Cancer|January 24, 2013
[Prognostic factors for patients with brain metastases]Romuald Le Scodan, Christophe Massard, Georges Noël
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
From theoretical synergy to clinical supra-additive toxicityJean-Charles Soria, Christophe Massard, Hassane Izzedine
Current Opinion in Oncology|April 9, 2014
Implementing precision medicine initiatives in the clinic: a new paradigm in drug developmentAntoine Hollebecque, Christophe Massard, Jean-Charles Soria
Current Opinion in Oncology|March 14, 2012
Vascular disrupting agents: a delicate balance between efficacy and side effectsAntoine Hollebecque, Christophe Massard, Jean-Charles Soria
Current Urology Reports|December 6, 2011
Targeted therapies in metastatic renal cell carcinoma: overview of the past yearMarine Gross-Goupil, Christophe Massard, Alain Ravaud
European Urology|January 31, 2022
Re: Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau DiseaseKarim Bensalah, Zine-Eddine Khene, Christophe Massard
Pageof 37